Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.

Abstract: The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol).

Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prophylaxis and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isoproply-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1 as a pharmaceutical composition for the prophylaxis and treatment of osteoporosis.

Abstract: A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described.

Abstract: An enteral nutrient gel that is excellent at maintaining its solid matter (gel) form in the stomach, does not readily disintegrate or dissolve with a change in pH, is stable in its physical properties even during long-term storage, and can be passed through a feeding tube. The enteral nutrient gel contains agar, alginic acid and/or a salt thereof, soybean protein or a hydrolysate thereof, calcium, magnesium, dextrin, and, optionally, an oligosaccharide, a disaccharide and/or a monosaccharide. A solid composition containing 8 to 30 wt % protein, 2 to 25 wt % fats, and 40 to 70 wt % dextrin is used in preparing the enteral nutrient gel.

Abstract: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining health in humans and animals. By using a composition which comprises a coenzyme Q being a mixture of a reduced coenzyme Q and an oxidized coenzyme Q with the proportion of the reduced coenzyme Q to the whole coenzyme Q of more than 95% by weight, the present invention can attain a high maximum blood concentration of a coenzyme Q as well as long maintenance of high concentration of coenzyme Q in blood for a prolonged period of time, and the area under the blood concentration curve (AUC) can be expanded.

Abstract: This invention relates to a pharmaceutical composition containing 4-[(4-thiazolyl)phenoxyl]alkoxy-benzamidine derivatives expressed by the following formula 1 for the prevention and treatment of osteoporosis and more particularly, to the use of 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-iso-propyl-2-methyl-1,3-thiazol-4-yl)phenoxyl]pentoxy}-benzamidine expressed by the following formula 1, which is known as an antagonist of leukotriene-B4 receptor, as a pharmaceutical composition for the prevention and treatment of osteoporosis. [Formula 1], wherein, R is a hydrogen atom or a hydroxy group.

Abstract: A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.

Abstract: The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. In another aspect of the invention, there is provided a method of preventing excessive release of matrix metalloproteinases from an inflammatory cell in a disease condition in a human or an animal by contacting the cell with a therapeutically effective amount of a noble metal in a crystalline form characterized by atomic disorder, or with a solution derived therefrom to provide a modulatory effect on one or more matrix metalloproteinases, wherein the one or more noble metals is formed with atomic disorder, and preferably in a nanocrystalline form.

Abstract: The present invention provides a method for skin care by orally administering a skin care agent comprising an ingestible carrier and natural-type N-acetylglucosamine obtainable by hydrolysis of chitin with an acid, an enzyme, or an acid and an enzyme, wherein the natural-type N-acetylglucosamine is contained in an amount of from 0.1 to 99.9% by weight, by which the moisture and tension of skin can be improved and the rough skin and fine wrinkles can be prevented or ameliorated. The skin care agent may be a skin care agent containing chitinoligosaccharide in an amount of from 0.1 to 20% by weight and natural-type N-acetylglucosamine in an amount of from 0.1 to 99.9% by weight; or a skin care agent containing collagen peptide in an amount of from 0.1 to 99.9% by weight and natural-type N-acetylglucosamine in an amount of from 0.1 to 99.9% by weight.

Abstract: The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba, and ginger, and synthetic chemical analogues thereof, for the treatment of a beta-Amyloid protein-induced disease.

Abstract: A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of cell-specific carbonic anhydrase enzymes in the brain, such as conditions associated with chronic neurodegenerative conditions including dementia such as Alzheimer's disease, which method includes the administering over an extended period of time, ranging from 6 months to 5 years, of a pharmaceutically effective, non-toxic amount of a compound that increases the presence of cell-specific carbonic anhydrase enzymes in the brain. That compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.

Abstract: The invention concerns the use of riluzole or one of its pharmaceutically acceptable salts for preventing and/or treating acoustic traumas and, in particular, different types of deafness and tinnitus.

Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.

Abstract: The invention relates to a compound of formula (I): wherein: X represents chlorine or fluorine or CF3, R represents hydrogen or a group and methods for using the same.

Abstract: Provided is a method of treating or ameliorating hypertension in an animal comprising administering an effective amount of a compound of formula I:

Abstract: Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Five compounds are here reported to be active in breaking AGE-protein cross-links. These compounds are L-bis-[4-(4-chlorobenzamido-phenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amido-cyclohexane-1-carboxylic acid (LR23); methylene bis [4,4′-(2-chlorophenylureido-phenoxyisobutyric acid)] (LR90); 5-arninosalicylic acid (5-ASA); and metformin. These compounds may be used to reverse the debilitating effects of those diseases in which AGEs are formed.

Abstract: The use of (+)-sibutramine in the treatment of depression, obesity, Parkinson's disease, cerebral function disorders and diabetes is described.

Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: [wherein R1, R2, R3, and R4 independently denote a hydrogen atom or a lower alkyl group, R5 denotes a hydrogen atom, a lower alkyl group, or a lower acyl group, X denotes a monosaccharide residue or an oligosaccharide residue which may have a lower alkyl group or a lower acyl group substituted for the hydrogen atom of the hydroxyl group of the saccharide residue, n denotes an integer of 0-6, and m denotes an integer of 1-6]. The agent, even in a small dosage, acts safely and effectively on the affected part and allows the hindrances of ischemic reperfusion induced in heart, stomach, small intestine, liver, spleen, kidney, brain, and skin, and the hindrance induced during the transplantation of an internal organ to be prevented and cured.

Abstract: The invention provides a method of treating a cognitive dysfunction comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b][1,5]benzodiazepine.

Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

Abstract: A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, comprising selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor and administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor.

Abstract: A method of-treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.

Abstract: The present invention provides a medicament for neurodegenerative diseases comprising zonisamide or an alkali metal salt thereof as an active ingredient. The present medicament can be used in the prevention and treatment of neurodegenerative diseases such as Parkinson's disease, Huntington's disease, choreic syndrome and dystonic syndrome in mammals (including human).

Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.

Abstract: Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(−)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.

Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

Abstract: It has been discovered that the stimulation of &bgr;-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising &bgr;-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by &bgr;-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of &bgr;-adrenergic receptors.

Abstract: The present invention has for its object to provide a medicinal composition comprising coenzyme Q10 as an active ingredient, which composition features an enhanced absorption after oral administration. The present invention is directed to a medicinal composition comprising coenzyme Q10 as an active ingredient with the reduced form of coenzyme Q10 accounting for more than 20 weight % of said coenzyme Q10.

Abstract: A method of treating age related behavorial problems in dogs is disclosed. The method involves administering adrafinil or a metabolite thereof to an animal in need of such treatment.

Abstract: The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of the formula ##STR1## in which R.sup.1 and R.sup.2 are independently hydroxy and alkoxy of one to four carbon atoms; and R.sup.3 and R.sup.4 are independently methyl or ethyl, or R.sup.3 and R.sup.4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.

Abstract: The use of a combination of an alpha RAR receptor-specific agonist ligand and a gamma RAR receptor-specific antagonist ligand to reduce the rate of apoptosis is disclosed.

Abstract: Disclosed are methods for treating urinary incontinence using enantiomerically enriched (S)-trihexyphenidyl.

Abstract: The invention relates to the use of hyperimmune milk derived from milk producing animals hyperimmunized with bacterial antigens including intestinal bacteria. The present hyperimmune milk effectively prevents the decline of immunological functions observed in aging or immunocompromised animals and prevents the translocation of indigenous enteric bacteria from the GI tract of immunocompromised or aged animals, thereby preventing indigenous infection. More specifically, the present hyperimmune milk is administered to an animal in an amount sufficient to effectively prevent translocation of indigenous enteric bacteria in, delay the onset of, lower the rate of, or restore the declining immune functions of, aging or otherwise immunocompromised animals.

Abstract: A method for simultaneously treating osteoporosis and hypertension in the same individual by the administration of pharmaceutically acceptable alkalinizing potassium salts, such as potassium bicarbonate, preferably in the form of a dietary supplement.

Abstract: A medicinal substance for increasing fertility in mammalian males and for use as an anti-microbial or anti-inflammatory agent by mammals produced by boiling radish leaves, radish stems or portions thereof in water for a period of time sufficient to produce a tea containing an extract from the radish leaves and stems or portions thereof. Alternatively, the radish leaves and stems may be placed in hot water for a period of time sufficient to produce a tea containing the extract. The resulting tea can be drunk hot or cold and may be stored in a refrigerator for extended periods of time for later use. Patients taking a daily dosage of this tea have shown greatly improved sperm density and improved motility and morphology after use for several weeks. Dosages of this tea are also effective in treating prostatitis. The preferred radish plant is the spring radish of the species Raphanus sativus. The leaves of other radish plants including wild and winter or oriental radishes may also be used.

Abstract: Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.

Abstract: A low buffer nutritional composition which is useful to reduce the incidence of colonization of pathogenic bacteria.

Abstract: Methods and compositions for stimulating the growth of osteoblasts are disclosed. A composition comprising platelet derived growth factor and vitamin D is applied to osteoblasts in an amount sufficient to stimulate their growth. The methods may be used to promote the growth of osteoblasts in vitro or to promote the healing of bone defects in vivo.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;are provided.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: A liquid nutritional product for trauma and surgery patients has a caloric density of about 1.2 to 1.5 Kcal/mL and a calorie to nitrogen ratio of about 112:1 to 145:1. A portion of the protein system comprises partially digested protein, and supplemental L-arginine provides about 1-3% of the total calories in the product. The lipid system has a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1.

Abstract: The invention relates to compounds of formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, cyclic amide as defined in the description,B represents, with the nitrogen and carbon atoms to which it is linked, saturated polycyclic structure as defined in the description,R represents hydrogen, optionally substituted lower alkyl, optionally substituted (4-imidazolyl)methyl, (3-pyrazolyl)methyl or optionally substituted (2-pyridyl)methyl,their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid.Medicinal products.

Abstract: Administration of a Growth Hormone Releasing factor (GRF) at effective dosage levels improves the mental function of attention or short term memory in a subject in need of the treatment. The method of treating comprises the administration to the subject of an effective mental function improving amount of a Growth Hormone Releasing Factor.

Abstract: New morpholine compounds of the formula: ##STR1## in which: X, bonded to the aromatic nucleus, represents halogen or trifluoromethyl and R' represents hydrogen, (C.sub.1 -C.sub.5)alkyl optionally including a double bond, or aralkyl; in racemic and enantiomeric forms, and physiologically tolerable acid addition salts theroef.These compounds and their physiologically tolerable salts can be used therapeutically especially in the treatment of ischaemic syndromes and cerebral ageing.

Abstract: From organs of embryonic mammalia a new extract of active ingredients is recovered which extract can be used for controlling a reduced blood flow through periperhic organs and through the brain and which extract can be also used for controlling acne vulgaris. The corresponding extracts are used as active ingredients of corresponding pharmaceutical preparations.The new pharmaceutically active extract is prepared according to a process in which polar substances having a molecular weight below 5000 are isolated from the embryonic mammalian organs avoiding any degradation of substances having a higher molecular weight. The finely divided embryonic mammalian organs are extracted with a mixture of water and a water soluble organic solvent which contains nor more than 30 vol.-% of water at an about neutral pH value for stirring and refluxing.

Abstract: Disclosed are e.g. certain novel 2-benzyl-3-(substituted)-phenoxypropylamines, their methods of synthesis and pharmaceutical compositions. Said compounds are useful as potent and centrally active serotonin uptake inhibitors for the treatment of psychotropic disorders, particularly depression.

Abstract: A method of treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.

Abstract: Morpholine compounds of the formula: ##STR1## in which R.sub.1 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, (C.sub.5 -C.sub.6)-cycloalkyl or (C.sub.2 -C.sub.6)-acyl; andR.sub.2 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, or (C.sub.2 -C.sub.3)-acyl; enantiomers and physiologically tolerable acid salts thereof.These compounds may be used therapeutically especially in the treatment of ischaemic syndromes and of cerebral ageing.